​Effective June 12, 2023, AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey, and AmeriHealth Administrators will update their medical policy on patisiran (Onpattro^®) and vutrisiran (Amvuttra™) for Commercial members.

This policy will be updated to include a new drug, vutrisiran (Amvuttra™), which was approved by the U.S. Food and Drug Administration in June 2022 and has coverage criteria that needs to be met. The updated policy will also include more coverage changes for patisiran (Onpattro^®), including the restriction of combination therapies with drugs that act similarly.

For more information, please view #08.01.50c: patisiran (Onpattro^®) and vutrisiran (Amvuttra™), which was published as a notification on March 14, 2023.